Turner's Syndrome
15
0
0
12
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
13.3%
2 terminated out of 15 trials
85.7%
-0.8% vs benchmark
20%
3 trials in Phase 3/4
8%
1 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (15)
Evaluation of Overall Compliance and Duration of Zomacton® Treatment With the Zomajet® Needle-free Device
Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years
A Clinical Study to Assess the Efficacy and Safety of DA-3002
Turner Syndrome: Genotype and Phenotype
The Effects of Hormones in Growth Hormone-Treated Girls With Turner Syndrome
Pubertal Induction in Individuals With Hypogonadism
Evaluation of the Adherence and the Patient Acceptability of Zomacton® Treatment With the Zomajet® Vision X Device
Initiating Transdermal Estradiol Therapy in Turner's Syndrome
Comparison of Aneuploidy Risk Evaluations
An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG
Oxandrolone Compared With a Placebo on Growth Rate in Girls With Growth Hormone-Treated Turner's Syndrome
Hormone Replacement Therapy to Treat Turner Syndrome
Effect of Biosynthetic Growth Hormone and/or Ethinyl Estradiol on Adult Height in Patients With Turner Syndrome
The Effects of Estrogen on Cognition in Girls With Turner Syndrome
Effect of Estrogen on Mental and Social Functioning in Girls With Turner's Syndrome